MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

Search

AbCellera Biologics Inc

Cerrado

SectorSalud

5.58 -4.12

Resumen

Variación precio

24h

Actual

Mínimo

5.52

Máximo

5.59

Métricas clave

By Trading Economics

Ingresos

11M

-35M

Ventas

13M

17M

Margen de beneficio

-203.272

Empleados

596

EBITDA

769K

-39M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+64.58% upside

Dividendos

By Dow Jones

Próximas Ganancias

6 nov 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

399M

1.7B

Apertura anterior

9.7

Cierre anterior

5.58

Noticias sobre sentimiento de mercado

By Acuity

43%

57%

123 / 371 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

AbCellera Biologics Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

19 oct 2025, 20:00 UTC

Adquisiciones, fusiones, absorciones

Infratil Agrees to NZ$437.7 Million Deal to Raise Contact Energy Stake

19 oct 2025, 23:44 UTC

Charlas de Mercado

Gold Edges Lower Amid Signs of U.S.-China Trade Tensions Easing -- Market Talk

19 oct 2025, 23:37 UTC

Charlas de Mercado

New Zealand's Core CPI Keeps Rate Cut Hopes Alive -- Market Talk

19 oct 2025, 23:36 UTC

Charlas de Mercado

Nikkei May Rise, Tracking Wall Street Gains -- Market Talk

19 oct 2025, 23:36 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

19 oct 2025, 23:09 UTC

Charlas de Mercado

Could Rio Tinto, BHP Ally to Defend Iron-Ore Pricing Power? -- Market Talk

19 oct 2025, 22:41 UTC

Adquisiciones, fusiones, absorciones

Luxury Fashion House Kering Confirms Beauty Deal With L'Oréal -- Barrons.com

19 oct 2025, 22:30 UTC

Ganancias

Stock Futures Rise Ahead of Major Week of Earnings -- Barrons.com

19 oct 2025, 22:18 UTC

Charlas de Mercado

Gold at $5,000 on Cards as Investors Get Comfortable -- Market Talk

19 oct 2025, 21:50 UTC

Charlas de Mercado

Infratil's Contact Stake Buy May Require Bigger Asset Sales -- Market Talk

19 oct 2025, 21:15 UTC

Charlas de Mercado

Investors Need to Change Narrative Toward Scales -- Market Talk

19 oct 2025, 19:34 UTC

Adquisiciones, fusiones, absorciones

Infratil's Contact Shareholding to Rise to 14.3% When Deal Completes

19 oct 2025, 19:34 UTC

Adquisiciones, fusiones, absorciones

Infratil to Issue New Shares Worth NZ$218.8 Million to TECT at NZ$12.43 Each

19 oct 2025, 19:33 UTC

Adquisiciones, fusiones, absorciones

Infratil Part-Funding Purchase of Contact Energy Stake With NZ$218.8 Million of Existing Debt

19 oct 2025, 19:32 UTC

Adquisiciones, fusiones, absorciones

Infratil Acquiring Additional Contact Energy Stake for NZ$8.95/Share

19 oct 2025, 19:32 UTC

Adquisiciones, fusiones, absorciones

Infratil Acquiring Contact Energy Stake for NZ$437.7 Million

19 oct 2025, 19:31 UTC

Adquisiciones, fusiones, absorciones

Infratil Acquiring TECT Holdings's Shareholding in Contact Energy

19 oct 2025, 19:31 UTC

Adquisiciones, fusiones, absorciones

Infratil to Acquire Additional 4.92% Stake in Contact Energy

19 oct 2025, 16:29 UTC

Ganancias

Elon Musk Pay Drama Heats Up Ahead of Tesla Earnings -- Barrons.com

19 oct 2025, 11:14 UTC

Ganancias

Zijin Mining 3Q Oper Income CNY86.49B; up 8.1% on Year>2899.HK

19 oct 2025, 11:14 UTC

Ganancias

Zijin Mining: Higher Sales of Gold, Copper Supported Results >2899.HK

19 oct 2025, 11:14 UTC

Ganancias

Zijin Mining 3Q Net CNY14.57B; up 57.1% on Year>2899.HK

18 oct 2025, 13:30 UTC

Adquisiciones, fusiones, absorciones

Deal Expected to Value Unit at Roughly $4B, Sources Say -- WSJ

18 oct 2025, 13:30 UTC

Adquisiciones, fusiones, absorciones

Deal Could Be Announced as Soon as Next Week, Sources Say -- WSJ

18 oct 2025, 13:30 UTC

Adquisiciones, fusiones, absorciones

Gucci Owner Kering Nears $4 Billion Sale of Beauty Unit to L'Oréal -- WSJ

18 oct 2025, 13:30 UTC

Adquisiciones, fusiones, absorciones

Gucci Parent Kering in Talks to Sell Beauty Business to L'Oréal, Sources Say -- WSJ

18 oct 2025, 08:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

17 oct 2025, 23:25 UTC

Adquisiciones, fusiones, absorciones

New Zealand's 'Golden Visa' Targets the Affluent in Search of Plan B -- Barrons.com

17 oct 2025, 22:15 UTC

Charlas de Mercado

Ulta's CFO Appointment Seen Supporting Growth -- Market Talk

17 oct 2025, 21:15 UTC

Charlas de Mercado

Greece Expected to Post Overall Budgetary Surplus This Year -- Market Talk

Comparación entre iguales

Cambio de precio

AbCellera Biologics Inc Esperado

Precio Objetivo

By TipRanks

64.58% repunte

Estimación a 12 meses

Media 9.2 USD  64.58%

Máximo 17 USD

Mínimo 5 USD

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para AbCellera Biologics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

7 ratings

6

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

1.99 / 2.635Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Very Strong Bearish Evidence

Largo Plazo

Weak Bearish Evidence

Sentimiento

By Acuity

123 / 371 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de AbCellera Biologics Inc

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
help-icon Live chat